Evidence map›Paper›PMID 39240335›Full record

ArticleThe Journal of experimental medicine2024

Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.

Raphaël Jeger-Madiot, Delphine Planas, Isabelle Staropoli, Hippolyte Debarnot, Jérôme Kervevan, Héloïse Mary, Camilla Collina, Barbara F Fonseca, Rémy Robinot, Stacy Gellenoncourt and 5 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Review
  3. Review
  4. iScience · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Innovative micro physiological systems for vaccine development.Human vaccines & immunotherapeutics · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Raphaël Jeger-MadiotControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0009-0009-3444-8536
Delphine PlanasVirus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0002-2509-9954
Isabelle StaropoliVirus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0001-8637-4545
Hippolyte DebarnotControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0009-0001-7261-8470
Jérôme KervevanControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0002-5070-022X
Héloïse MaryBiomaterials and Microfluidics Core Facility, Institut Pasteur, Université de Paris Cité , Paris, France.ORCID 0000-0003-1171-3260
Camilla CollinaControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0009-0002-2632-0136
Barbara F FonsecaControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0001-6403-4099
Rémy RobinotControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0002-3651-0171
Stacy GellenoncourtControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0003-1896-7212
Olivier SchwartzVirus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0002-0729-1475
Lorna EwartEmulate Inc , Boston, USA.ORCID 0000-0002-8258-7460
Michael BscheiderRoche Pharma Research & Early Development, Roche Innovation Center Basel , Basel, Switzerland.ORCID 0000-0001-7808-3270
Samy GobaaBiomaterials and Microfluidics Core Facility, Institut Pasteur, Université de Paris Cité , Paris, France.ORCID 0000-0002-0125-8674
Lisa A ChakrabartiControl of Chronic Viral Infections Group, Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique UMR3569 , Paris, France.ORCID 0000-0002-1895-3630

Funding

Emulate S-RD21002Fondation de France PR-166156French Agency for AIDS and Emerging Diseases Research (ANRS-MIE) ECTZ213626Institut Carnot Pasteur Microbe & SantéInstitut Pasteur PFR7Pasteur COVID-19 RP call
6 · The paper itself

Abstract

Predicting the immunogenicity of candidate vaccines in humans remains a challenge. To address this issue, we developed a lymphoid organ-chip (LO chip) model based on a microfluidic chip seeded with human PBMC at high density within a 3D collagen matrix. Perfusion of the SARS-CoV-2 spike protein mimicked a vaccine boost by inducing a massive amplification of spike-specific memory B cells, plasmablast differentiation, and spike-specific antibody secretion. Features of lymphoid tissue, including the formation of activated CD4+ T cell/B cell clusters and the emigration of matured plasmablasts, were recapitulated in the LO chip. Importantly, myeloid cells were competent at capturing and expressing mRNA vectored by lipid nanoparticles, enabling the assessment of responses to mRNA vaccines. Comparison of on-chip responses to Wuhan monovalent and Wuhan/Omicron bivalent mRNA vaccine boosts showed equivalent induction of Omicron neutralizing antibodies, pointing at immune imprinting as reported in vivo. The LO chip thus represents a versatile platform suited to the preclinical evaluation of vaccine-boosting strategies.

Indexed as

COVID-19COVID-19 VaccinesMemory B CellsmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCD4-Positive T-LymphocytesHumansLab-On-A-Chip DevicesLiposomesLymphoid TissueNanoparticlesRNA, MessengerAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesLipid NanoparticlesLiposomesmRNA VaccinesRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic

Identifiers

PMID39240335
PMCPMC11383861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.